Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients

Nat Commun. 2014 Oct 30;5:5317. doi: 10.1038/ncomms6317.


Here, we demonstrate that electroporation-enhanced immunization with a rationally designed HPV DNA vaccine (GX-188E), preferentially targeting HPV antigens to dendritic cells, elicits a significant E6/E7-specific IFN-γ-producing T-cell response in all nine cervical intraepithelial neoplasia 3 (CIN3) patients. Importantly, eight out of nine patients exhibit an enhanced polyfunctional HPV-specific CD8 T-cell response as shown by an increase in cytolytic activity, proliferative capacity and secretion of effector molecules. Notably, seven out of nine patients display complete regression of their lesions and viral clearance within 36 weeks of follow up. GX-188E administration does not elicit serious vaccine-associated adverse events at all administered doses. These findings indicate that the magnitude of systemic polyfunctional CD8 T-cell response is the main contributing factor for histological, cytological and virological responses, providing valuable insights into the design of therapeutic vaccines for effectively treating persistent infections and cancers in humans.

Publication types

  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibody Formation
  • CD8-Positive T-Lymphocytes / immunology
  • Cervical Intraepithelial Neoplasia / therapy*
  • Cervical Intraepithelial Neoplasia / virology
  • Female
  • Humans
  • Immunity, Cellular
  • Middle Aged
  • Oncogene Proteins, Viral / immunology
  • Papillomavirus Infections / therapy*
  • Papillomavirus Vaccines / therapeutic use*
  • Uterine Cervical Neoplasms / therapy*
  • Uterine Cervical Neoplasms / virology
  • Vaccines, DNA / therapeutic use*
  • Young Adult


  • GX-188 vaccine
  • Oncogene Proteins, Viral
  • Papillomavirus Vaccines
  • Vaccines, DNA